## **Genome-wide screens reveal shared and strain-specific genes that facilitate**

### **enteric colonization by** *Klebsiella pneumoniae*

- 3 Bettina H Cheung<sup>1</sup>, Arghavan Alisoltani<sup>1,2,3</sup>, Travis J Kochan<sup>1</sup>, Marine Lebrun-Corbin<sup>1</sup>,
- 4 Sophia H Nozick<sup>1</sup>, Christopher MR Axline<sup>1</sup>, Kelly ER Bachta<sup>2</sup>, Egon A Ozer<sup>2,3</sup>, and Alan

5 R Hauser $1,2#$ 

- **1** Department of Microbiology-Immunology, Northwestern University, Feinberg
- School of Medicine, Chicago, IL, USA
- 8 <sup>2</sup> Division of Infectious Diseases, Department of Medicine, Northwestern
- University, Feinberg School of Medicine, Chicago, IL, USA
- <sup>3</sup> 10 <sup>3</sup> Center for Pathogen Genomics and Microbial Evolution, Havey Institute for
- Global Health, Northwestern University Feinberg School of Medicine, Chicago,

IL, USA

- **# Corresponding author: Alan R Hauser (ahauser@northwestern.edu)**
- **RUNNING TITLE** Colonization factors across 3 *Klebsiella* strains

# **ABSTRACT**

Gastrointestinal (GI) colonization by *Klebsiella pneumoniae* is a risk factor for subsequent infection as well as transmission to other patients. Additionally, colonization is achieved by many strain types that exhibit high diversity in genetic content. Thus, we aimed to study strain-specific requirements for *K. pneumoniae* GI colonization by applying transposon insertion sequencing to three classical clinical strains: a carbapenem-resistant strain, an extended-spectrum beta-lactamase producing strain,

and a non-epidemic antibiotic-susceptible strain. The transposon insertion libraries were screened in a murine model of GI colonization. At three days post-inoculation, 27 genes were required by all three strains for colonization. Isogenic deletion mutants for three genes/operons (*acrA*, *carAB*, *tatABCD*) confirmed colonization defects in each of the three strains. Additionally, deletion of *acrA* reduced bile tolerance *in vitro*, while complementation restored both bile tolerance *in vitro* and colonization ability *in vivo*. Transposon insertion sequencing suggested that some genes were more important for colonization of one strain than the others. For example, deletion of the sucrose porin-encoding gene *scrY* resulted in a colonization defect in the carbapenemase-producing strain but not in the extended-spectrum beta-lactamase producer or the antibiotic-susceptible strain. These findings demonstrate that classical *K. pneumoniae* strains use both shared and strain-specific strategies to colonize the mouse GI tract. **IMPORTANCE** *Klebsiella pneumoniae* is a common cause of difficult-to-treat infections due to its propensity to express resistance to many antibiotics. For example, carbapenem-resistant *K. pneumoniae* (CR-Kp) has been named an urgent threat by the United States Centers for Disease Control and Prevention. Gastrointestinal colonization of patients with *K. pneumoniae* has been linked to subsequent infection, making it a key process to control in prevention of multidrug-resistant infections. However, the bacterial factors which contribute to *K. pneumoniae* colonization are not well understood. Additionally, individual strains exhibit large amounts of genetic diversity, begging the question of whether some colonization factors are strain-dependent. This study identifies the enteric colonization factors of 3 classical strains using transposon mutant

screens to define a core colonization program for *K. pneumoniae* as well as detecting strain-to-strain differences in colonization strategies.

#### **INTRODUCTION**

As multidrug-resistant bacteria continue to pose a looming threat to our ability to treat infections, alternative methods for controlling disease burden—such as infection prevention—are increasingly important. For *Klebsiella pneumoniae*, a highly multidrug-resistant bacteria, gastrointestinal (GI) colonization is a risk factor for subsequent infection. Patients are prone to infections caused by the strains they carry and may also spread them to other hospitalized patients<sup>1,2</sup>. Thus, GI colonization by *K. pneumoniae* is an attractive target for infection prevention.

The genes required for *K. pneumoniae* gut colonization are not well understood. Studies of intestinal colonization are complicated by the fact that this species exhibits substantial genetic diversity. While the average *K. pneumoniae* genome contains about  $5000-6000$  genes, only ~1700 are shared by most strains<sup>3,4</sup>. Studies have identified 58 colonization factors for individual strains<sup>5-7</sup>, but whether *K. pneumoniae*'s genetic diversity gives rise to strain-to-strain differences in GI colonization strategies remains unclear.

Two broad categories of *K. pneumoniae* strains have been described: classical and hypervirulent. Of the classical strains, several have achieved global dominance and are referred to as high-risk clones. Two such high-risk clones are the ST45 and ST258 sequence types. ST45 strains frequently produce extended-spectrum beta-lactamases (ESBLs), making them resistant to most beta-lactams except carbapenems. Many

ST258 strains produce carbapenemases, causing a significant portion of carbapenem-67 resistant infections worldwide<sup>8</sup>. While it is conceivable that the global success of these lineages has resulted in part from their capacity to better colonize the GI tract, how their colonization strategies might differ from those of antibiotic-susceptible strains has not been investigated.

Here, we selected three representative clinical classical strains of *K. pneumoniae* to investigate GI colonization by lineages of varying epidemicity and antibiotic resistance. We used transposon insertion sequencing to identify genes in each strain that were required for GI colonization in a mouse model. We found that a subset of genes was required by all three strains, but each strain relied on a much larger set of additional genes that were dispensable for the other strains. Thus, the set of genes, and therefore presumed GI colonization strategies, vary substantially across phylogenetically distinct *K. pneumoniae* strains. **RESULTS Three clinical strains of** *K. pneumoniae* **with distinct genetic and phenotypic** 

**characteristics** 

We selected three clinical isolates of *K. pneumoniae* representative of strains with varying levels of epidemic spread and antibiotic resistance. First, we chose CRE-84 166, a carbapenem-resistant strain of the ST258 high-risk clone with the *bla*<sub>KPC</sub> gene, which was isolated from bronchioalveolar lavage. Second, we selected Z4160, an ESBL 86 producer isolated from the bloodstream with both a widespread ESBL gene ( $b/a<sub>CTX-M-15</sub>$ ) and an epidemic sequence type (ST45). Third, we chose KPN46, a non-epidemic,

antibiotic-susceptible bloodstream isolate (ST433). The sizes of the CRE-166, Z4160, and KPN46 genomes were 6.00, 5.56, and 5.63 Mb, respectively. The core genome shared between them was 4.96 Mb (4,662 coding sequences [CDS]), leaving CRE-166, Z4160, and KPN46 with 1.04, 0.63, 0.69 Mb (1183, 623, and 749 CDS) of accessory genetic content (Figure 1). Thus, CRE-166, Z4160, and KPN46 represented three clinical strains with phenotypic and genomic diversity suitable for subsequent studies of *K. pneumoniae* GI colonization.

### **A clinically relevant murine model of GI colonization**

To model hospitalized patients receiving antibiotics and to induce robust fecal shedding of *K. pneumoniae* in C57BL/6 mice, we administered an antibiotic regimen prior to oral gavage with bacteria. Vancomycin, one of the most highly utilized antibiotics 99 in the United States<sup>9</sup>, was administered through daily intraperitoneal injection for 5 days 100 (350 mg/kg, equivalent to a human dose of 1 g/day)<sup>10</sup> (Figure 2A). In contrast to other screens for GI colonization factors in which antibiotics were administered through 102 drinking water and throughout the screen<sup>5-7</sup>, we opted for injections to control dosage to each mouse and to allow for precise adjustments in future studies. We also ceased administration prior to *K. pneumoniae* inoculation to investigate colonization after 105 antibiotic exposure. Following the last dose of vancomycin,  $10^8$  colony forming units (CFU) of CRE-166 were inoculated by orogastric gavage. *K. pneumoniae* was then selectively cultured from feces by plating on lysogeny broth (LB) agar supplemented 108 with carbenicillin, an antibiotic to which all K. pneumoniae are resistant<sup>4</sup>. Culture of feces on this medium prior to inoculation with *K. pneumoniae* yielded no colonies, confirming specificity for experimentally introduced *K. pneumoniae* (Supplemental

111 Figure 1A). These conditions supported 10<sup>10</sup> CFU/g fecal shedding of *K. pneumoniae* in 112 the first week followed by shedding of  $10^7$  CFU/g for at least 60 days post-gavage in both male and female mice (Figure 2B). At Day 14, no CFU could be detected in the lung, liver, or spleen, indicating there was no dissemination from the gut (Supplemental Figure 1B). Additionally, throughout the infection, mice did not exhibit signs of illness, suggesting that they were colonized rather than infected.

To ensure these conditions would produce similar levels of GI colonization with KPN46 and Z4160, we individually inoculated CRE-166, KPN46, and Z4160 into mice. Fecal burdens were similar across 14 days (Figure 2C). These results indicated that the vancomycin-treated mice were a robust model of *K. pneumoniae* GI colonization.

To determine whether transposon insertion sequencing experiments would be informative in our model, we next ensured that mutants would not randomly drop out of the fecal output due to bottlenecks rather than colonization defects. To this end, we constructed a marked CRE-166 strain by inserting an apramycin-resistance cassette into the chromosomal Tn7 site. This marked strain did not have a growth defect in LB when compared to the parental strain (Supplemental Figure 2A). To mimic the presence of a single transposon mutant within the pool of total mutants in a screen, we spiked this marked strain into an inoculum at a ratio of 1:100,000 with the parental strain. Next, we measured the ratio of the marked strain to total *K. pneumoniae* recovered from the feces of the mice. At Day 3 post-gavage, the marked strain was still detectable, suggesting the absence of a bottleneck significant enough to bias transposon sequencing results (Supplemental Figures 2B & 2C). However, at subsequent timepoints, we failed to recover the marked strain from some of the mice, indicating

greater bottlenecks. We therefore chose Day 3 post-gavage as the timepoint for

transposon sequencing experiments.

#### **Generation of highly saturated transposon mutant libraries**

To perform genome-wide screens for GI colonization factors, we generated transposon mutant libraries in all three *K. pneumoniae* strains. The transposon vector pSAM*erm* was modified to express hygromycin resistance (pSAM*hygSDM*) to allow for selection of transposition in all three strains. Libraries with over 145,000 mutants were generated. An initial assessment of library quality was performed by randomly selecting 32 colonies from each library and identifying transposon insertion sites with arbitrary PCR. Unique insertion sites for at least 26 colonies for each strain were successfully identified, and no colonies had more than one insertion site, indicating the libraries were of high quality.

## **Screening the mutant libraries for GI colonization factors** *in vivo*

We gavaged each of the three transposon mutant libraries into mice pre-treated with vancomycin. A portion of the inoculum was saved as the "input pool." At Day 3, we collected fecal pellets, or the "output pools." Input pool sequencing demonstrated that over 82% of coding sequences had at least one insertion, and on average, each gene had 5 insertions. Coverage was distributed across chromosomes (Supplemental Figure 3), confirming that all libraries were well-saturated.

Insertion site sequencing reads were then processed using a modified version of 154 the previously described ESSENTIALS pipeline<sup>11</sup>. We first analyzed the input pools to identify "essential genes" required for the bacteria to grow in LB. A total of 487 genes

were identified as essential in all three strains, but a substantial number of genes were essential in only one or two strains (Figure 3A, Supplemental Table 1). Between 14- 18% of CDS in each strain were found to be essential, comparable to the estimates of 159 11-17% reported for other strains of *K. pneumoniae*<sup>5,12-14</sup>.

To determine which genes each strain utilized for establishing GI colonization, we compared the total number of insertion reads per gene in the Day 3 output pool to 162 those of the input pools. We focused on genes that had a less than  $-2 \log_2($  fold-change) (logFC) in output vs. input insertion reads and a false discovery rate (FDR) less than 0.05 (Figure 4, Supplemental Table 2). Multidimensional scaling (MDS) plots of input and Day 3 output pools demonstrated that the input pools were closely related and distinct from the Day 3 output pools for each strain (Supplemental Figure 4), indicating our approach was technically robust.

Twenty-seven genes were used by all three strains for GI colonization (Figure 3B). However, many genes were used by only one strain to establish colonization: 88 for CRE-166, 83 for Z4160, and 34 for KPN46. Intriguingly, most genes identified as important for colonization in at least one strain were present in all 3 strains. That is, only 22.6% of colonization genes for CRE-166, 3.3% for KPN46, and 6.8% for Z4160 were absent from the genomes of the other strains, suggesting that these strains mostly rely on shared genes to establish GI colonization, but use different sets of these genes for this purpose.

To determine whether these colonization genes were also found in broader populations of *K. pneumoniae* strains, we calculated a core genome (genes shared by 178  $\,$  95% of strains) from a set of 323 previously described strains<sup>4</sup>. Upon comparison with

this broader core genome, somewhat larger percentages of the colonization genes for each strain were now considered accessory genes: 25.8% for CRE-166, 16.1% for KPN46, and 15.4% for Z4160. However, most genes required for colonization by each strain were still genes shared across *K. pneumoniae* strains.

In addition to genes required for colonization, we also identified genes which, upon disruption with a transposon, conferred a colonization advantage (red points in Figure 4). There were 7 genes found to confer an advantage when disrupted in all 3 strains (Supplemental Table 2). Four were involved in maltose transport (*malT*, *malEFG*) while the other three had regulatory roles (*proQ*, *prc*, and *rspR*).

#### **Classification of GI colonization factors**

To better understand the core colonization program in *K. pneumoniae*, we focused on the 27 genes important for colonization across all three strains (Table 1). As expected, we identified genes involved in anaerobic metabolism (e.g., *adhE, fnr, focA).* We also found genes involved in other metabolic pathways, including *mtlD* (mannitol-1- phosphate dehydrogenase) and *carAB*, which encode the subunits of carbamoyl phosphate synthase that are responsible for the first committed step in synthesis of 195 pyrimidine and arginine<sup>15</sup> *carA* was identified in two strains and *carB* in the remaining strain. *tatA* and *tatC* (folded protein secretion apparatus<sup>16</sup>) and *acrA* (efflux pump<sup>17</sup>) were also identified.

To examine the pathways that strains relied on for colonization, we assigned Kyoto Encyclopedia of Genes and Genomes (KEGG) identifiers to all genes in each strain and determined which pathways were enriched among colonization hits. These

pathways fell into a few broad categories: metabolism, antimicrobial resistance, protein secretion, and environmental sensing (Figure 5). Metabolic capacities played an important role in the ability of bacteria to colonize the gut, but individual pathways identified differed by strain. Additionally, the colonization factors for CRE-166 and KPN46 were enriched for two-component systems, which may have played a role in metabolic adjustments caused by environmental sensing in the GI tract. In terms of antimicrobial resistance pathways, two strains (CRE-166 and KPN46) were reliant on genes that conferred resistance to cationic antimicrobial peptides (CAMPs), which are released by colonic epithelium and are similar to microcins released by the microbiota. Thus, defense against host and microbiome factors is likely key to colonization by *K. pneumoniae*. KPN46 colonization factors were enriched for genes for resistance to beta-lactams, including efflux pumps, which play a role in the efflux of toxic compounds. Finally, protein export (the Tat secretion system) was enriched for KPN46 and Z4160, suggesting that secreted proteins may enhance colonization.

## **Validation of colonization genes using isogenic mutants**

To validate our screen, we created isogenic mutants of 3 genetic loci—*acrA*, *carAB*, and *tatABCD*—required for GI colonization in all 3 strains (Table 1). These loci were chosen because they represent different functional groups: antimicrobial resistance, metabolism, and secretion. We generated isogenic mutants in which the coding sequence of the target was replaced by an apramycin-resistance cassette. We verified that these apramycin-resistant mutants did not have growth defects in LB when grown individually (Supplemental Figure 5). Of these mutants, only the *tatABCD* mutant had a slight defect in LB when competed against their marked (hygromycin-resistant)

parental strains (Supplemental Figure 6). Then, we inoculated 1:1 mixtures of the marked parental strains and mutants into the mouse model of GI colonization and enumerated CFU in the feces at Day 3 (the screen timepoint) to calculate competitive indices (CI). To characterize the effects of these mutants at later timepoints, we also followed the fecal burdens to Day 14.

In all three strain backgrounds, *acrA* mutants displayed significant colonization defects at Day 3 (validating our screen) as well as beyond to Day 14 (Figure 6A-C). We constructed a complemented strain with an unmarked deletion of the *acrA* locus, inserting *acrA* along with its upstream region and a downstream apramycin-resistance cassette into the chromosomal Tn7 site. This complement rescued the colonization defect (Figure 6D).

The *carAB* deletion mutants were similarly tested in competition with their parental strains. At Day 3, each *carAB* mutant exhibited colonization defect, continuing to Day 14 for CRE-166 and Z4160 (Figure 6E-G). For the KPN46 mutant, greater variability in CI was observed at later timepoints, suggesting the existence of a priority effect in the second week, during which mutants that initially established themselves tended to do very well while the others did progressively more poorly. Due to technical limitations, a *carAB* complement could not be constructed. However, we performed whole genome sequencing on all mutants, confirming that the CRE-166 and Z4160 mutants did not have off-site mutations likely to be responsible for observed phenotypes. For KPN46, sequencing indicated that two nonsynonymous mutations emerged during the course of mutant generation. We performed an *in vivo* competition experiment between two marked KPN46 parental strains—one with these off-site

mutations and one without—to show that the mutations did not confer a colonization defect (Supplemental Figure 7). These data indicate that the *carAB* deletions are responsible for the colonization defects observed in Figure 6E-G.

Finally, deletion of the *tatABCD* operon also significantly decreased colonization capacities, both at Day 3 and throughout subsequent days (Figure 6H-J). Insertion of the *tatABCD* operon at the Tn7 site fully rescued the colonization defect (Figure 6K). Thus, we verified our ability to detect shared factors essential for GI colonization.

In addition to shared factors, we wanted to confirm strain-specific colonization factors. Hemolysin expression-modulating protein, encoded by *hha*, is a transcriptional regulator which scored as a hit in Z4160 but not in KPN46 and CRE-166. We generated *hha* deletion mutants in both Z4160 and KPN46, neither of which had *in vitro* growth defects (Supplemental Figure 5). At Day 3, the Δ*hha* mutant had a statistically significant colonization defect in Z4160 (Figure 6L). In KPN46, the Δ*hha* mutant had a slightly less severe colonization defect that was not statistically significant (Figure 6M).

As a second strain-specific factor, we selected *scrY*, which encodes for a sucrose porin, and which was identified in our screen as a colonization factor for CRE-166 but not KPN46 or Z4160. We created in-frame deletions to preserve the remainder of the operon downstream from *scrY* and found that CRE-166Δ*scrY* but not KPN46Δ*scrY* or Z4160Δ*scrY* had a colonization defect (Figure 6O-Q). Together, these data indicate that colonization factors may differ in their importance from strain to strain. Finally, we also selected one target that exhibited a colonization *advantage* upon

disruption. We chose *malT*, the transcriptional regulator for maltose uptake and

metabolism. A *malT* deletion mutant in CRE-166 did not have a growth advantage in LB (Supplemental Figure 5), but this deletion conferred a substantial colonization advantage over the parent strain *in vivo* (Figure 6N), indicating our screen was also valid for detection of genes that confer colonization advantages.

#### **Deletion of** *acrA* **reduces resistance to ox bile**

We further explored how one of our colonization genes, *acrA,* may contribute to GI colonization. As *acrA* encodes a component of an efflux pump that contributes to bile 276 resistance in other GI pathogens<sup>18</sup>, we tested whether our *acrA* mutant was more sensitive to bile. At 2 and 24 hours after inoculation into 10% bile, the marked parental strain grew significantly better than the CRE-166Δ*acrA*::AprR mutant (Figure 7). We also generated a CRE-166Δ*acrA* mutant in which the apramycin-resistance cassette was removed from the Δ*acrA* allele; this mutant also showed a growth defect in bile. A complemented strain (CRE-166Δ*acrA* Tn7::*acrA*) generated from this mutant showed that complementation rescued resistance to bile. Together, these data suggest that *acrA* supports *K. pneumoniae* GI colonization by providing resistance to bile.

## **DISCUSSION**

In this study, we aimed to answer the following question: does the genetic diversity of *K. pneumoniae* affect the colonization strategies of different strains? We compared three clinically-relevant strains (a globally distributed ST258 strain with a carbapenemase gene, an epidemic ST45 strain with an ESBL gene, and a non-epidemic antibiotic-susceptible strain) and identified a core set of genes used by all three strains to colonize the GI tract. However, we found other genes and pathways unique to one or two strains, highlighting the diversity of colonization strategies in this genetically diverse species. In particular, we confirmed the importance of three different factors (*acrA*, *carAB, tatABCD*) in colonization for all three strains to validate our screens.

Our results defined a core colonization program of 27 genes utilized by all 3 strains. Most of these genes (16 of 27) were related to metabolism, as expected since metabolic adaption to the anaerobic colon is a prerequisite for successful colonization. In addition, we also identified three genetic loci involved in pyrimidine and purine synthesis (*carAB* and *purC*/*purH*, respectively). Beyond metabolic genes, all strains relied on *yeiE*, which encodes a transcriptional activator. The genes regulated by YeiE in *K. pneumoniae* are not well characterized, but in *Salmonella enterica* this activator also controls GI colonization<sup>19</sup>, targeting flagellar genes (which *K. pneumoniae* does not possess). In addition, *tatA* and *tatC*, which encode components of the Tat folded-protein secretion apparatus, were identified as elements of the core colonization program, suggesting secreted factors may contribute to colonization, as they do for several gut 306 pathogens<sup>20-23</sup>. In particular, the Tat-secreted peptidoglycan amidases, AmiA and AmiC, are necessary for colonization by *S. typhimurium<sup>24</sup>*, and *amiC* was identified in our CRE-166 screen (Supplemental Table 2). However, disruption of the Tat system also 309 destabilizes the cell envelope<sup>25</sup>, decreasing resistance to bile acids<sup>20</sup>. Genes encoding the porin OmpC (*ompC*) and components of the Tol-Pal system (*tolA* and *pal*) were also identified as critical for colonization for all 3 strains. In addition to allowing diffusion of small solutes, OmpC is responsible for maintaining outer membrane leaflet 313 asymmetry<sup>26</sup>. In a different fashion, the Tol-Pal system also aids in maintaining the

314 integrity of the outer membrane<sup>27</sup>. Deletion of *pal* in *K. pneumoniae* increases sensitivity 315 to bile, one of the host-derived stresses encountered in the GI tract<sup>28</sup>. A few other genes implicated in bile resistance (*cvpA* and *acrA*) were critical for colonization. In summary, the core GI colonization program of *K. pneumoniae* is composed of genes involved in energy generation, nucleotide biosynthesis, protein secretion, membrane homeostasis, and bile resistance.

We found many genes that contributed to colonization by one or two strains but not by all three strains. For instance, pathway analysis revealed that unlike the other two strains, Z4160 colonization factors were enriched for alanine, aspartate, and glutamate metabolism pathways. In addition, we found that CRE-166 depends on the sucrose porin *scrY* for colonization whereas Z4160 and KPN46 do not. It is possible that redundancy in either sucrose uptake or functional redundancy in other metabolic pathways can compensate for *scrY* deletion in Z4160 and KPN46 but not CRE-166. These findings support our hypothesis that colonization strategies differ between strains of *K. pneumoniae*.

The identification of *acrA* as necessary for GI colonization in all three strains has translational implications. AcrA is the periplasmic subunit of the tripartite efflux pumps 331 that contain TolC and AcrB or AcrD<sup>17</sup>. In *E. coli* and *S. enterica*, these pumps export a 1332 large variety of substrates, including multiple classes of antibiotics and bile acids<sup>17,29</sup>. We demonstrated that the *acrA* mutant in CRE-166 was more susceptible to bile (Figure 7), suggesting a similar function in *K. pneumoniae*. Furthermore, the *acrA* deletion mutants were undetectable at 14 days post-inoculation in most of our competition experiments (Figure 6A-C). Because of its role in antibiotic resistance, the AcrAB efflux

pump has been extensively studied, and several small molecule inhibitors are in varying 338 stages of pre-clinical development<sup>30</sup>. We postulate that these inhibitors may have efficacy in preventing or eradicating *K. pneumoniae* GI colonization.

CRE-166 belongs to the globally disseminated ST258 group of carbapenemase-producing strains, and there is substantial interest in understanding how these strains successfully colonize patients. Jung and colleagues previously performed transposon insertion sequencing on a different ST258 strain, MH258, and our results have similarities. First, both studies found that disruption of genes involved in maltose metabolism conferred a fitness advantage in the GI tract. The lambda phage uses 346 maltoporin LamB as its receptor , so it is possible that the maltose system serves as a receptor for a lytic phage, bacteriocin, or other bacterial competition systems. Second, 9 of 35 MH258 colonization factors were also important for CRE-166. However, we also found 150 genes to be important for GI colonization with CRE-166 that were not identified for MH258. These differences may reflect genetic variation between the ST258 strains or differences in screen analysis and antibiotic regimens.

Our study had several limitations. All transposon insertion sequencing screens have a propensity to miss secreted factors because of trans-complementation. This may be one reason why we did not detect Type VI secretion systems in our screens even 355 though they have been shown to contribute to colonization<sup>32,33</sup>. Interestingly, we did detect *amiC*, which encodes for a Tat-secreted substrate, but this substrate may remain localized within bacteria. Additionally, our screen was performed on Day 3 of colonization—the latest timepoint at which we did not observe a substantial bottleneck. Factors necessary for colonization on Day 3 may be different from those necessary for

longer term colonization. However, these factors would likely be relevant for the development of prophylactic therapies against colonization, and our mutant studies show that deletion of several genes required for Day 3 colonization were also necessary at Day 14 (Figure 6). Additionally, we found that one strain-specific factor, *scrY*, had a stronger phenotype in targeted deletion and validation than another factor, *hha*. This may be explained by outlier read counts that have an inflated effect on the averages used to calculate log fold change. This type of technical limitation of the analysis may explain why *tolC,* which is usually complexed to *acrA,* was identified as a colonization factor for CRE-166 but not the two other strains. Another limitation is that we used as our input pool the mutant library that was inoculated into mice rather than a mutant library passaged in LB. As a result, some of the genes we identified as necessary for GI colonization were likely necessary for normal bacterial growth in rich medium. Such genes, although mechanistically less interesting, are in the strictest sense still necessary for colonization. Our study used only 3 strains, all of which were classical strains. The conserved genome between these clinical strains was 4558 CDS, which is larger than the core content between larger collections of *K. pneumoniae* strains (around 1700 CDS). Additional studies will be necessary to determine whether our findings can be extrapolated to a larger number of *K. pneumoniae* strains, including hypervirulent strains. Finally, our studies were done with C57BL/6 mice; experiments with different mouse strains are necessary to determine whether mouse background affects the genes necessary for colonization.

In conclusion, our study found that while different strains of *K. pneumoniae* rely on different genes and pathways to colonize the GI tract, there is a core set of



# **MATERIALS AND METHODS**

# **Bacterial strains and cultures**

- CRE-166, KPN46, and Z4160 are *K. pneumoniae* clinical isolates from
- Northwestern Memorial Hospital in Chicago collected between 2014 and 2015. CRE-
- 391 166 and KPN46 were previously described  $34,35$ , whereas Z4160 was first used in the
- current study. *E. coli* strain PIR1 was used for cloning, and *E. coli* β3914
- 393 (diaminopimelic acid auxotroph) was used to mate plasmids into *K. pneumoniae*<sup>36,37</sup>.
- $B$ acteria were grown in LB 37 $\degree$ C unless otherwise stated. When appropriate, the following antibiotics were added: carbenicillin (100 μg/mL), hygromycin (100 μg/mL), or apramycin (50 μg/mL). Medium for β3914 was supplemented with 10 μg/mL of DAP.
- **Preparation of complete genomes**

Genomic DNA was extracted from CRE-166, KPN46, and Z4160 and sequenced on Illumina and Nanopore platforms to create complete genomes. Annotation was 400 performed using the NCBI Prokaryotic Genome Annotation Pipeline (Z4160)<sup>38</sup> or Prokka 401 (CRE-166 and KPN46)<sup>39</sup>.

**Identification of shared genes**

To identify genes shared between the three *K. pneumoniae* strains, we used the program Spine and defined shared coding sequences as those with >85% sequence 405 homology between strains<sup>40</sup>. We defined the core genome of *K. pneumoniae* as 406 sequences present in 95% of 323 strains from a previous study<sup>4</sup> (with homologous genes defined as those with >85% similarity between strains).

### **Murine model of GI Colonization**

Six- to eight-week-old C57BL/6 mice (Jackson Laboratories) received 5 daily intraperitoneal injections of vancomycin (350 mg/kg, Hospira) unless otherwise 411 indicated. For gavage with individual strains, inocula of 10 $^8$  CFU in 50 µl of PBS were used. Mice received daily cage changes to minimize coprophagy. CFU were enumerated by homogenization of fecal pellets in PBS with the Benchmark Bead Blaster 24 (Benchmark Scientific) followed by serial dilution and plating on LB agar with carbenicillin.

Transposon insertion sequencing experiments were performed as above. Frozen aliquots of the transposon libraries were revived for 2 hours in 25 mL of LB. CFU in fecal pellets were quantified as above, and DNA was extracted from the homogenates with the Maxwell 16 system.

For competitive colonization experiments, inocula of 1:1 mixtures of a 421 hygromycin-resistant parental strain and an isogenic apramycin-resistant mutant (10) CFU each) were created. Fecal CFU burdens were enumerated as above by plating on LB agar with hygromycin or apramycin. Competitive indices (CIs) were calculated as the ratio of mutant CFU to parent strain CFU, normalized to the input ratio.

- Mice were housed in a containment ward of the Center for Comparative Medicine at Northwestern University. Experiments were approved by the Northwestern University Institutional Animal Care and Use Committee in compliance with ethical regulations.
- **Construction of transposon mutant libraries**

A suicide plasmid suitable for Himar1 mariner transposon mutagenesis in highly 430 antibiotic-resistant strains was generated from pSAM*erm* (gift from G. Pier<sup>41</sup>). Briefly, pSAM*erm* was modified by replacement of the erythromycin-resistance cassette with a 432 hygromycin-resistance cassette (HygR), and the Mmel sites in HygR were removed by site-directed mutagenesis. The resulting plasmid, pSAM*hygSDM*, was transformed into *E. coli* β3914 to generate a donor strain for conjugation with *K. pneumoniae* recipient strains. To select for transconjugants and eliminate β3914, we plated on LB agar 436 supplemented with hygromycin (but lacking DAP) and incubated at  $37^{\circ}$ C overnight. Colonies were scraped and resuspended in LB with 25% glycerol. The resulting library 438 was stored at  $-80^{\circ}$ C.

## **Arbitrary PCR for library quality control**

Genomic DNA was extracted from 32 randomly selected colonies from each library, and two rounds of nested PCR were performed to amplify the transposon insertion site for subsequent Sanger sequencing. Primer sequences are listed in Supplemental Table 3.

## **Preparation of DNA for transposon insertion sequencing**

DNA extracted from fecal pellets was prepared for insertion site sequencing 446 using the method of Kazi and colleagues<sup>42</sup>. Three replicates for each input (technical)

- and output (biological) pool were prepared, plus one technical replicate of an output
- 448 sample. DNA was sheared to  $\sim$ 250 bp fragments with the E220 ultrasonicator (Covaris),
- and insertion sites were amplified with addition of capture/sequencing sites and
- barcodes. Final library pool concentrations were quantified with Kapa library
- quantification (Roche) and sequenced on an Illumina MiSeq.

## **Transposon insertion sequencing data analysis**

- 453  $\mu$  A modified version of the previously described ESSENTIALS pipeline<sup>11</sup> was used
- to identify genes necessary for growth in LB and genes that contributed to
- 455  $\degree$  colonization<sup>43</sup>.

#### **Pathway analysis**

- KEGG identifiers were assigned to all genes using BlastKOALA, and KEGG
- 458 pathways were assigned using KEGG Mapper $44,45$ . A hypergeometric test was
- conducted in R (v4.2.2) to determine which KEGG pathways were enriched for
- colonization factors.

#### **Isogenic mutant construction**

Deletion mutants were created using lambda red recombination as previously 463 described<sup>46</sup>. All mutants were confirmed by whole-genome sequencing on Illumina platforms.

#### **Bile assays**

Dehydrated ox bile was resuspended in water (10% w/v, Sigma) and filtered 467 through a 0.2 µm filter. Strains were grown to an  $OD_{600}$  of 1.0, and 1 mL of each culture

- 468 was pelleted and resuspended in 1 mL PBS. Each strain was inoculated (100 μl) into
- 469 900 µl of 10% ox bile, PBS, or LB and incubated with shaking at  $37^{\circ}$ C. At 0, 2, 4, and 24
- 470 hours, aliquots were removed and plated on LB agar for CFU enumeration.

# 471 **Data availability**

- 472 The complete genomes of CRE-166, KPN46, and Z4160 have been deposited,
- 473 and respective accession numbers are: GCA\_016797255.2, GCA\_021272285.2,
- 474 GCA\_030019695.1.

# 475 **ACKNOWLEDGEMENTS**

476 We thank Mark Mandel for the β3914 strain and David Amici for comments on

477 the manuscript. Support for this work was provided by the National Institutes of Health

478 grants R01 AI118257, U19 AI135964, K24 AI04831, R21 AI164254, R21 AI153953

479 (A.R.H) and T32GM008152 (B.H.C), American Cancer Society grant 134251-CSDG-20-

480 053-01-MPC (K.E.R.B), and American Heart Association grant 837089 (T.K.).

# 481 **BIBLIOGRAPHY**

482 1. Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant 483 *Klebsiella pneumoniae* bloodstream infection among rectal carriers: a prospective observational 484 multicentre study. Clinical Microbiology and Infection 2014;20:1357–62.

485 2. Gorrie CL, Mirčeta M, Wick RR, et al. Gastrointestinal Carriage Is a Major Reservoir of 486 *Klebsiella pneumoniae* Infection in Intensive Care Patients. Clinical Infectious Diseases: An 487 Official Publication of the Infectious Diseases Society of America 2017;65:208.

- 488 3. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance 489 framework and genotyping tool for *Klebsiella pneumoniae* and its related species complex. 490 Nature Communications 2021;12:1–16.
- 491 4. Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population 492 structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to 493 public health. Proceedings of the National Academy of Sciences of the United States of America
- 494 2015;112:E3574.

495 5. Jung H-J, Littmann ER, Seok R, et al. Genome-Wide Screening for Enteric Colonization 496 Factors in Carbapenem-Resistant ST258 *Klebsiella pneumoniae*. mBio 2019;10. 497 6. Maroncle N, Balestrino D, Rich C, Forestier C. Identification of *Klebsiella pneumoniae* 498 genes involved in intestinal colonization and adhesion using signature-tagged mutagenesis. 499 Infection and Immunity 2002;70:4729–34. 500 7. Struve C, Forestier C, Krogfelt KA. Application of a novel multi-screening signature-501 tagged mutagenesis assay for identification of *Klebsiella pneumoniae* genes essential in 502 colonization and infection. Microbiology 2003;149:167–76. 503 8. Cerqueira GC, Earl AM, Ernst CM, et al. Multi-institute analysis of carbapenem resistance 504 reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. 505 Proceedings of the National Academy of Sciences of the United States of America 506 2017;114:1135. 507 9. Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating National Trends in 508 Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012. JAMA Internal Medicine 509 2016;176:1639–48. 510 10. Administration. UFD. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials 511 f. 2018. 512 11. Zomer A, Burghout P, Bootsma HJ, Hermans PWM, van Hijum SAFT. ESSENTIALS: 513 Software for Rapid Analysis of High Throughput Transposon Insertion Sequencing Data. PLOS 514 ONE 2012;7:e43012. 515 12. Jana B, Cain AK, Doerrler WT, et al. The secondary resistome of multidrug-resistant 516 *Klebsiella pneumoniae*. Scientific Reports 2017;7. 517 13. Ramage B, Erolin R, Held K, et al. Comprehensive Arrayed Transposon Mutant Library of 518 *Klebsiella pneumoniae* Outbreak Strain KPNIH1. J Bacteriol 2017;199. 519 14. Bachman MA, Breen P, Deornellas V, et al. Genome-Wide Identification of Klebsiella 520 pneumoniae Fitness Genes during Lung Infection. MBio 2015;6:e00775. 521 15. Charlier D, Nguyen Le Minh P, Roovers M. Regulation of carbamoylphosphate synthesis 522 in *Escherichia coli*: an amazing metabolite at the crossroad of arginine and pyrimidine 523 biosynthesis. Amino Acids 2018;50:1647–61. 524 16. Palmer T, Berks BC. The twin-arginine translocation (Tat) protein export pathway. 525 Nature Reviews Microbiology 2012;10:483–96. 526 17. Li X-Z, Plésiat P, Nikaido H. The Challenge of Efflux-Mediated Antibiotic Resistance in 527 Gram-Negative Bacteria. Clinical Microbiology Reviews 2015;28:337. 528 18. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by *Escherichia coli*. J 529 Bacteriol 1997;179:2512. 530 19. Westerman TL, McClelland M, Elfenbein JR. YeiE Regulates Motility and Gut Colonization 531 in *Salmonella enterica* Serotype *Typhimurium*. mBio 2021;12. 532 20. Reynolds MM, Bogomolnaya L, Guo J, et al. Abrogation of the twin arginine transport 533 system in *Salmonella enterica* serovar *Typhimurium* leads to colonization defects during 534 infection. PloS One 2011;6:e15800. 535 21. Zhang L, Zhu Z, Jing H, et al. Pleiotropic effects of the twin-arginine translocation system 536 on biofilm formation, colonization, and virulence in *Vibrio cholerae*. BMC Microbiology 537 2009;9:114.

538 22. Lavander M, Ericsson SK, Bröms JE, Forsberg Å. The Twin Arginine Translocation System 539 Is Essential for Virulence of *Yersinia pseudotuberculosis*. Infection and Immunity 2006;74:1768. 540 23. Rajashekara G, Drozd M, Gangaiah D, Jeon B, Liu Z, Zhang Q. Functional characterization 541 of the twin-arginine translocation system in *Campylobacter jejuni*. Foodborne Pathogens and 542 Disease 2009;6:935–45. 543 24. Fujimoto M, Goto R, Hirota R, et al. Tat-exported peptidoglycan amidase-dependent cell 544 division contributes to *Salmonella Typhimurium* fitness in the inflamed gut. PLoS Pathogens 545 2018;14. 546 25. Stanley NR, Findlay K, Berks BC, Palmer T. *Escherichia coli* Strains Blocked in Tat-547 Dependent Protein Export Exhibit Pleiotropic Defects in the Cell Envelope. J Bacteriol 548 2001;183:139. 549 26. Chong Z-S, Woo W-F, Chng S-S. Osmoporin OmpC forms a complex with MlaA to 550 maintain outer membrane lipid asymmetry in *Escherichia coli*. Molecular Microbiology 551 2015;98:1133–46. 552 27. Szczepaniak J, Press C, Kleanthous C. The multifarious roles of Tol-Pal in Gram-negative 553 bacteria. FEMS Microbiology Reviews 2020;44:490. 554 28. Hsieh P-F, Liu J-Y, Pan Y-J, et al. *Klebsiella pneumoniae* Peptidoglycan-Associated 555 Lipoprotein and Murein Lipoprotein Contribute to Serum Resistance, Antiphagocytosis, and 556 Proinflammatory Cytokine Stimulation. Journal of Infectious Diseases 2013;208:1580–9. 557 29. Nishino K, Latifi T, Groisman EA. Virulence and drug resistance roles of multidrug efflux 558 systems of *Salmonella enterica* serovar *Typhimurium*. Molecular Microbiology 2006;59:126–41. 559 30. Sharma A, Gupta VK, Pathania R. Efflux pump inhibitors for bacterial pathogens: From 560 bench to bedside. Indian Journal of Medical Research 2019;149:129. 561 31. Randall-Hazelbauer L, Schwartz M. Isolation of the Bacteriophage Lambda Receptor 562 from *Escherichia coli*. J Bacteriol 1973. 563 32. Calderon-Gonzalez R, Lee A, Lopez-Campos G, et al. Modelling the Gastrointestinal 564 Carriage of *Klebsiella pneumoniae* Infections. MBio 2023;e0312122. 565 33. Merciecca T, Bornes S, Nakusi L, et al. Role of *Klebsiella pneumoniae* Type VI secretion 566 system (T6SS) in long-term gastrointestinal colonization. Scientific Reports 2022;12:16968. 567 34. Bulman ZP, Krapp F, Pincus NB, et al. Genomic Features Associated with the Degree of 568 Phenotypic Resistance to Carbapenems in Carbapenem-Resistant *Klebsiella pneumoniae*. 569 mSystems 2021;6. 570 35. Kochan TJ, Nozick SH, Medernach RL, et al. Genomic surveillance for multidrug-resistant 571 or hypervirulent *Klebsiella pneumoniae* among United States bloodstream isolates. BMC 572 Infectious Diseases 2022;22. 573 36. Wang N, Ozer EA, Mandel MJ, Hauser AR. Genome-Wide Identification of *Acinetobacter*  574 *baumannii* Genes Necessary for Persistence in the Lung. mBio 2014;5. 575 37. Le Roux F, Binesse J, Saulnier D, Mazel D. Construction of a *Vibrio splendidus* Mutant 576 Lacking the Metalloprotease Gene *vsm* by Use of a Novel Counterselectable Suicide Vector. 577 Applied and Environmental Microbiology 2007;73:777. 578 38. Tatusova T, DiCuccio M, Badretdin A, et al. NCBI prokaryotic genome annotation 579 pipeline. Nucleic Acids Research 2016;44:6614. 580 39. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 581 2014;30:2068–9.

582 40. Ozer EA, Allen JP, Hauser AR. Characterization of the core and accessory genomes of 583 *Pseudomonas aeruginosa* using bioinformatic tools Spine and AGEnt. BMC Genomics 584 2014;15:737.

585 41. Skurnik D, Roux D, Aschard H, et al. A comprehensive analysis of *in vitro* and *in vivo*  586 genetic fitness of *Pseudomonas aeruginosa* using high-throughput sequencing of transposon 587 libraries. PLoS Pathogens 2013;9:e1003582.

588 42. Kazi MI, Schargel RD, Boll JM. Generating Transposon Insertion Libraries in Gram-589 Negative Bacteria for High-Throughput Sequencing. JoVE (Journal of Visualized Experiments) 590 2020:e61612.

591 43. Ozer EA. egonozer/essentials\_local: Version 2.1. 2.1 ed: Zenodo; 2023.

- 592 44. Kanehisa M, Sato Y, Morishima K. BlastKOALA and GhostKOALA: KEGG Tools for
- 593 Functional Characterization of Genome and Metagenome Sequences. Journal of Molecular 594 Biology 2016;428:726–31.
- 595 45. Kanehisa M, Sato Y, Kawashima M. KEGG mapping tools for uncovering hidden features
- 596 in biological data. Protein Science : a Publication of the Protein Society 2022;31:47–53.
- 597 46. Huang T-W, Lam I, Chang H-Y, Tsai S-F, Palsson BO, Charusanti P. Capsule deletion via a
- 598 λ-Red knockout system perturbs biofilm formation and fimbriae expression in *Klebsiella*
- 599 *pneumoniae* MGH 78578. BMC Research Notes 2014;7:13.

600

#### 601



602

#### 603 **FIGURE LEGENDS**

604

605 **Figure 1** Unique and shared coding sequences between 3 strains of *K. pneumoniae*. 606 The software program Spine was used to identify coding sequences with at least 85%

607 homology in the strains indicated.

608 **Figure 2** Mouse model of GI colonization with *K. pneumoniae*. (A) Schematic of the *in* 

609 *vivo* model. Mice were administered 5 days of 350 mg/kg intraperitoneal vancomycin

610 injections before orogastric gavage with 10<sup>8</sup> CFU *K. pneumoniae*. Fecal samples were

611 collected after gavage and CFU enumerated. (B) Fecal burden of CRE-166 following

612 gavage into male (square) or female (circle) mice with (red) or without (black)

613 vancomycin treatment prior to gavage.  $n = 5$  for each group. (C) Fecal burdens of

614 strains CRE-166, KPN46, and Z4160 in mouse model of GI colonization. n = 10 for each

615 group. Line indicates median. Limit of detection was  $10^2$  CFU/g feces, denoted by a dotted line.

- **Figure 3** Genes required for growth in LB and for GI colonization. Transposon mutant
- libraries were screened in a mouse model of GI colonization. n = 3 for inputs and
- outputs for each strain. (A) Shared and unique essential genes for each strain. (B)
- Shared and unique genes for which transposon insertions resulted in reduced fitness in
- 621 the gut. Genes had a  $log_2$  fold change  $\leq$  -2 and a false discovery rate  $\leq$  0.05.
- **Figure 4** Volcano plots showing results of transposon insertion sequencing experiments
- in mice. Genes in which insertions were associated with decreased GI colonization
- (blue dots) and increased colonization (red dots) for (A) CRE-166, (B) KPN46, and (C)
- Z4160 are shown. Labeled points indicate targets that were chosen for the creation of
- isogenic mutants. FDR, false discovery rate; FC, fold change.
- **Figure 5** Pathways used for GI colonization in 3 strains of *K. pneumoniae*. Kyoto
- Encyclopedia of Genes and Genomes (KEGG) identifiers were assigned to all genes in
- the genomes of CRE-166, KPN46, and Z4160. The enrichment ratio (Enrich Ratio) was
- calculated as the ratio of genes in the target list belonging to the specified KEGG
- pathway to the total number of genes in the pathway in the genome. A hypergeometric
- test was used to determine false discovery rate (FDR), and FDR < 0.05 was considered
- significant.
- **Figure 6** Competitive colonization between parent strains and isogenic mutants to
- validate genes identified in transposon insertion screens. Mice were treated with 5 days
- of vancomycin prior to gavage with 1:1 mixtures of marked parent strain (hygromycin-
- resistance cassette at the Tn7 site) and isogenic mutant (substitution of open reading
- frame with apramycin-resistance cassette [A-N] or an unmarked in-frame deletion [O-
- 639 Q]) of the target gene(s).  $n = 10$  for A-G and L-N.  $n \ge 9$  for H-K and O-Q. Asterisks
- 640 denote significance by one-sample t-tests with Dunn correction where  $* p < 0.05$ ,  $** p <$
- 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001, and "ns" indicates not significant. Limit of detection
- 642 was a competitive index of  $10^{-7}$  for A-N and  $10^{-3}$  for O-Q, denoted with a dotted line. Log(competitive index) = 0, or equal recovered CFU of parental strain and mutant, is
- marked with a dashed line.
- **Figure 7** Resistance of CRE-166 and *acrA* mutants to 10% ox bile. Strains were inoculated into 10% ox bile (w/v), incubated, and CFU were plated for enumeration at 647 the indicated timepoints.  $n = 3$  biological replicates. Line denotes median.  $*$  indicates p < 0.05 in two-way ANOVA with Tukey's HSD test.

















- CRE-166 Tn7:: HygR
- CRE-166∆acrA::AprR
- CRE-166AacrA
- CRE-166∆acrA Tn7::acrA